Zihong Chen
Overview
Explore the profile of Zihong Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
1085
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
He N, Tian L, Jin J, Liu Y, Li L, Wang X, et al.
Noncoding RNA Res
. 2025 Feb;
11:209-219.
PMID: 39896342
Background: Myasthenia gravis (MG) is an autoimmune disorder caused by antibodies that target the postsynaptic muscle membrane. Recent evidence suggests that genetic variants and long noncoding RNAs (lncRNAs) play crucial...
2.
McGinnis J, Ortiz-Guzman J, Guevara M, Mallannagari S, Belfort B, Bao S, et al.
bioRxiv
. 2024 Nov;
PMID: 39605617
The development of cell-type-specific gene therapy vectors for treating neurological diseases holds great promise, but has relied on animal models with limited translational utility. We have adapted an organotypic model...
3.
Bao Y, Yuan X, Chen Z, Yang Y, Zheng Y, Wang Y
Microbiol Resour Announc
. 2024 Sep;
13(10):e0034024.
PMID: 39248544
The draft genome sequence of YAF008 was reported. The genome size of YAF008 was 34.7M bp with 50.72% GC content. The genome resource will support future research into potential secondary...
4.
Luo H, Yi G, Tang H, Chen L, Hu L, Yang D, et al.
Sci Rep
. 2024 Aug;
14(1):18839.
PMID: 39138312
Cisplatin is the most commonly used platinum-based treatment for nasopharyngeal carcinoma (NPC). However, its clinical application is limited owing to its nephrotoxicity and gastrointestinal reactions. Proton pump inhibitors (PPIs) have...
5.
Li L, Li D, Jin J, Xu F, He N, Ren Y, et al.
J Neuroinflammation
. 2024 Aug;
21(1):197.
PMID: 39113081
Background: Myasthenia gravis (MG) is an autoimmune disease characterized by pathogenic antibodies that target structures of the neuromuscular junction. The evidence suggests that the regulation of long noncoding RNAs (lncRNAs)...
6.
He J, Luo G, Liu S, Chen L, Chen Z, Zhang B, et al.
Transl Oncol
. 2024 Jul;
48:102058.
PMID: 39079408
Background: The efficacy of immunotherapy plus neoadjuvant chemotherapy and concurrent chemoradiotherapy (CCRT) for locally advanced nasopharyngeal carcinoma (LA-NPC) has not been reported. This study retrospectively compared the efficacy of tislelizumab...
7.
Zhang Y, Chen Z, Chen G, Huang Y, Yang Y, Fang W, et al.
Clin Lung Cancer
. 2024 Jun;
25(7):e357-e361.e17.
PMID: 38945800
Background: Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have significant antitumor activity to advanced non-small-cell lung cancer (NSCLC) patients with classic EGFR mutations. However, EGFR-TKI monotherapy shows poor...
8.
Shi M, Pang L, Zhou H, Mo S, Sheng J, Zhang Y, et al.
Lung Cancer
. 2024 May;
192:107818.
PMID: 38763102
Introductions: The 2021 WHO Classification of Thoracic Tumors recognized SMARCA4-deficient undifferentiated thoracic tumors (SMARCA4-dUT) as a distinct entity that shows a striking overlap in demographic and molecular profiles with SMARCA4-deficient...
9.
Xu X, Chen Z, Bartman C, Xing X, Olszewski K, Rabinowitz J
Cell Chem Biol
. 2024 May;
31(5):932-943.e8.
PMID: 38759619
Nucleotides perform important metabolic functions, carrying energy and feeding nucleic acid synthesis. Here, we use isotope tracing-mass spectrometry to quantitate contributions to purine nucleotides from salvage versus de novo synthesis....
10.
Zhang Y, Chen Z, Liu Y, Han L, Jiang W, Wang Q, et al.
Cancer Med
. 2024 Apr;
13(7):e7175.
PMID: 38597130
Background: Combination of chidamide and anti-PD-L1 inhibitor produce synergistic anti-tumor effect in advanced NSCLC patients resistant to anti-PD-1 treatment. However, the effect of chidamide plus envafolimab has not been reported....